# KLOW peptide references: the cited literature behind every claim | Clinic KLOW

> KLOW peptide references: the full, cited literature behind the four arms — KPV, GHK-Cu, BPC-157 and TB-500 — with DOIs and PubMed links for every study summarized on this site.

Every quantitative statement on this site traces to one of these published studies. Verify them yourself.

## How to use this list

Every numbered citation in the body copy of this site maps to one entry here, with a DOI or PubMed link so you can check the source. The studies are grouped, in your head, by arm — KPV, GHK-Cu, BPC-157 and TB-500/thymosin beta-4 — but the one thing to keep in front of you is the absence: there is no entry for the four-peptide KLOW blend itself, because no controlled blend study exists.

A few entries carry a caution worth repeating. The thymosin beta-4 studies describe the full-length native protein, not the short TB-500 fragment marketed as it. The AHK-Cu hair study tests an analog of GHK-Cu, not GHK-Cu itself. We cite both honestly as context, never as direct blend or component proof.

## References

[1] Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/
[2] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[3] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. https://pubmed.ncbi.nlm.nih.gov/18061177/
[4] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Res Int. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[5] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
[6] Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. (retrospective case series, n=16). https://pubmed.ncbi.nlm.nih.gov/34324435/
[7] Trachy RE, Fors TD, Pickart L, Uno H. The hair follicle-stimulating properties of peptide copper complexes. Results in C3H mice. Ann N Y Acad Sci. 1991;642:468-469. https://pubmed.ncbi.nlm.nih.gov/1809108/
[8] Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. https://pubmed.ncbi.nlm.nih.gov/16583442/
[9] Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839. (tests AHK-Cu, an analog of GHK-Cu). https://pubmed.ncbi.nlm.nih.gov/17703734/
[10] Philp D, et al. Thymosin beta 4 induces hair growth via stem cell migration and differentiation. Ann N Y Acad Sci. 2007;1112:95-103. https://pubmed.ncbi.nlm.nih.gov/17947589/
[11] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40131143/
[12] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[13] Mao S, Huang J, Li J, Sun F, Zhang Q, Cheng Q, Zeng W, Lei D, Wang S, Yao J. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Front Pharmacol. 2025;16:1551843. https://pmc.ncbi.nlm.nih.gov/articles/PMC12263609/
[14] Sosne G, et al. Activation of pro-resolving pathways mediate the therapeutic effects of thymosin beta-4. Front Immunol. 2024;15:1458684. https://pubmed.ncbi.nlm.nih.gov/39380984/
[15] Wang L, et al. Thymosin beta4 improves the survival of cutaneous flaps of rat and activates Wnt/beta-catenin signaling. Arch Med Sci. 2024. https://doi.org/10.5114/aoms/186188
[16] Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. (full-length thymosin beta-4, not the TB-500 fragment). https://pubmed.ncbi.nlm.nih.gov/20536472/
[17] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[18] Wang Y, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. https://pubmed.ncbi.nlm.nih.gov/36588717/
[19] Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res. 2011;60(1):79-86. https://pmc.ncbi.nlm.nih.gov/articles/PMC3016279/
[20] Getting SJ, Christian HC, Lam CW, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. https://pubmed.ncbi.nlm.nih.gov/12750433/

---

A warm, plain-English reading desk for the four-peptide KLOW research record — KPV, GHK-Cu, BPC-157 and TB-500 read one honest arm at a time, every claim walked back to its study and the empty space where the blend trial should be left in plain sight; no clinic behind the desk and nothing here dosed, dispensed, or sold.